Project Grant R37CA300969
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $819K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This Project Grant award, titled "Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining its Regulation and Cellular Interactions", is funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) for $241,884.00. The award will be carried out by the Dana-Farber Cancer Institute, Inc. (DFCI) from September 3, 2025 through August 31, 2030. The project aims to characterize the role of the non-classical HLA-E molecule in immune evasion by diffuse large...
- This federal Project Grant award, valued at $695,997.00 and awarded on Aug 18, 2025, supports research conducted by Mayo Clinic Arizona under the Cardiovascular Diseases Research program (CFDA 93.837) administered by the National Heart, Lung, and Blood Institute. The research aims to investigate the role of the Programmed Cell Death 4 (PDCD4) gene in mitigating doxorubicin-induced cardiotoxicity, a common side effect of anthracycline chemotherapy drugs. The project utilizes a juvenile mouse...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $817,829 aims to improve the quality of life of lymphoma survivors. The award will fund a randomized controlled trial to test the efficacy of a virtual, resilience-based group program (SMART3RP-Lymphoma) for lymphoma survivors during their early post-treatment period (0-2 years after active treatment). The goal is to address the significant psychosocial challenges and declines...
- This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
- This federal Project Grant award for $992,425.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to AVM Biotechnology, Inc., a woman-owned small business located in Seattle, Washington. The funding supports the development of AVM0703, a proprietary high-concentration formulation of dexamethasone sodium phosphate, as a novel bridging therapy to stabilize tumor burden and improve outcomes for relapsed/refractory diffuse large B-cell...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
- This $4,753,460 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized Phase 2 clinical trial evaluating the PI3KD inhibitor roginolisib in combination with venetoclax and rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) patients. The study will be conducted by the Dana-Farber Cancer Institute, Inc. (DFCI), a prestigious non-profit cancer research center in Boston, Massachusetts....
- This federal Project Grant award of $226,435.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports a Phase II randomized study to assess the optimal duration of maintenance therapy for patients with light chain (AL) amyloidosis. The study will evaluate the efficacy of 6 months versus 18 months of daratumumab maintenance following initial daratumumab-cybord induction treatment. Key objectives include assessing event-free survival, hematological response,...
- This Project Grant award, valued at $415,500.00 and awarded by the National Cancer Institute under the federal Cancer Treatment Research program (CFDA 93.395), is funding research into peptide-doxorubicin (DOX) conjugates to mitigate cardiotoxicity and overcome drug resistance in cancer. The key objectives are to investigate the mechanisms by which five peptide-DOX conjugates can effectively target and overcome DOX-resistant cancer cells while reducing cardiotoxicity, in order to enhance...